CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

BioStem's Q4-2024 revenue expected to rise 794% YoY, with full-year net revenue increasing 1,702%. Read why I'm bullish on ...

INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal ...

How is Aadhaar-EPIC linking relevant to the UPSC exam? What significance do topics like CAR T-cell therapy, smart cities ...